Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome

International Journal of Molecular Epidemiology and Genetics

Volumn 2, Issue 2, 2011, Pages 185-195

  Peethambaram, Prema ^a   Fridley, Brooke L ^a   Vierkant, Robert A ^a   Larson, Melissa C ^a   Kalli, Kimberly R ^a   Elliott, Elaine A ^a   Oberg, Ann L ^a   White, Kristin L ^a   Rider, David N ^a   Keeney, Gary L ^a   Cunningham, Julie M ^a   Hartmann, Lynn C ^a   Goode, Ellen L ^a  

^a Mayo Clinic   (United States)

Author keywords

Drug related variants; Metabolism; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTATHIONE TRANSFERASE M1; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; XERODERMA PIGMENTOSUM GROUP C PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; DNA POLYMORPHISM; FEMALE; HISTOPATHOLOGY; HUMAN; INTRON; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARY CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

EID: 79958160457     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Hoskins WJ, Bundy BN, Thigpen JT and Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in smallvolume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992; 47: 159-166.
3. McGuire V, Jesser CA and Whittemore AS. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 2002; 84: 399-403.
4. Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H, Harnett PR, Brown R, DeFazio A and Chenevix-Trench G. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 2008; 14: 5594-5601.
5. Darcy KM, Tian C, Ambrosone CB, Krivak TC, Armstrong D, Bookman MA, Davis W, Zhao H, Moysich K and DeLoia JA. A Gynecologic Oncology Group study of associations between polymorphisms in ABC transporter genes (ABCB1, ABCC2 and ABCG2) and outcome in advanced stage epithelial ovarian cancer treated with platinum and taxane chemotherapy. J Clin Oncol 2009; 27: s293.
6. Harris JW, Rahman A, Kim BR, Guengerich FP and Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994; 54: 4026-4035.
7. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ and Harris JW. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994; 54: 5543-5546.
8. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI and Goldstein JA. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11: 597-607.
9. Marsh S, Paul J, King CR, Gifford G, McLeod HL and Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007; 25: 4528-4535.
10. Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BA, Easton DF and Pharoah PP. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 2002; 62: 3052-3057.
11. Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H and Sanchez-Cespedes M. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 2006; 24: 4333-4339.
12. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L and Christiani DC. Excision repair crosscomplementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10: 4939-4943.
13. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S and Lenz HJ. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61: 8654-8658.
14. Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Sun Y, Xu BH and Lin DX. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer]. Zhonghua Yi Xue Za Zhi 2005; 85: 972-975.
15. Nagle CM, Chenevix-Trench G, Webb PM and Spurdle AB. Ovarian cancer survival and polymorphisms in hormone and DNA repair pathway genes. Cancer Lett 2007; 251: 96-104.
16. Song H, Hogdall E, Ramus SJ, Dicioccio RA, Hogdall C, Quaye L, McGuire V, Whittemore AS, Shah M, Greenberg D, Easton DF, Kjaer SK, Pharoah PD and Gayther SA. Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival. Clin Cancer Res 2008; 14: 1090-1095.
17. Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB and DeLoia JA. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 2008; 26: 3598-3606.
18. Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS and Kang SB. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean populationbased study. Gynecol Oncol 2009; 113: 264-269.
19. Medeiros R, Pereira D, Afonso N, Palmeira C, Faleiro C, Afonso-Lopes C, Freitas-Silva M, Vasconcelos A, Costa S, Osorio T and Lopes C. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione Stransferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 2003; 8: 156-161.
20. Sellers TA, Schildkraut JM, Pankratz VS, Vierkant RA, Fredericksen ZS, Olson JE, Cunningham JM, Taylor W, Liebow M, McPherson CP, Hartmann LC, Pal T and Adjei AA. Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2536-2543.
21. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L and Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004; 74: 106-120.
22. The International HapMap Consortium. The International HapMap Project. Nature 2003; 426: 789-796.
23. [NIEHS SNPs. NIEHS Environmental Genome Project, University of Washington, Seattle, 358 WA (URL: http://egp.gs.washington.edu) [June 2009].
24. Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, Fridley BL, Vierkant RA, Armasu SM, White KL, Keeney GL, Cliby WA, Rider DN, Kelemen LE, Jones MB, Peethambaram PP, Lancaster JM, Olson JE, Schildkraut JM, Cunningham JM and Hartmann LC. Inherited determinants of ovarian cancer survival. Clin Cancer Res 2010; 16: 995-1007.
25. [Oliphant A, Barker DL, Stuelpnagel JR and Chee MS. BeadArray technology: enabling an accurate, cost-effective approach to highthroughput genotyping. Biotechniques 2002; Suppl: 56-58, 60-51.
26. Steemers FJ and Gunderson KL. Illumina, Inc. Pharmacogenomics 2005; 6: 777-782.
27. Cox DR. Regression models and life tables (with discussion). Journal of Royal Statistical Society, Series B 1972; 34: 187-220.
28. Freidlin B, Zheng G, Li Z and Gastwirth JL. Trend tests for case-control studies of genetic markers: power, sample size and robustness. Hum Hered 2002; 53: 146-152.
29. Gauderman WJ, Murcray C, Gilliland F and Conti DV. Testing association between disease and multiple SNPs in a candidate gene. Genet Epidemiol 2007; 31: 383-395.
30. Schaid DJ, Rowland CM, Tines DE, Jacobson RM and Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-434.
31. Barrett JC, Fry B, Maller J and Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
32. Green H, Soderkvist P, Rosenberg P, Horvath G and Peterson C. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J Pharm Sci 2008; 97: 2045-2048.
33. Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H and Katsaros D. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 2007; 25: 5172-5179.